GU Cancers 2025 | Comparing survival outcomes in high-risk clear cell versus non-clear cell RCC
Giacomo Musso, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses a multicenter study comparing survival outcomes in high-risk localized clear cell (ccRCC) and non-clear cell renal cell carcinoma (nccRCC) treated with adjuvant pembrolizumab. Those with high-grade or T3 nccRCC had similar 5-year cancer-specific and overall survival rates to ccRCC. Histology was not an independent predictor of mortality, highlighting the need for further trials evaluating adjuvant systemic therapy in high-risk nccRCC to improve treatment strategies. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
